ClinicalTrials.gg
CompletedNCT04578873Updated Oct 10, 2022

Phase 1 Oral QPX7831 SAD and MAD in Healthy Adults

A Phase 1 interventional study of QPX7831 and placebo comparator in Bacterial Infections, sponsored by Qpex Biopharma, Inc.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-10.

Sponsored by Qpex Biopharma, Inc. (part of Shionogi) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Aug 2022, 4 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Bacterial Infections by Shionogi — none open to participants now, none under way, none of them phase 3. Bacterial Infections · Shionogi.

Started
2021
with 2 others
Phase 1
9 of 10
none open now
Registered
4th of 10
by date

Among the 10 studies in Bacterial Infections by Shionogi, this one is one of 3 that started in 2021, is one of 9 in phase 1, and was the 4th registered.

Bacterial Infections

586 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

None of the 10 studies in Bacterial Infections by Shionogi is open now. The open studies under Bacterial Infections, anywhere →

Where they have run

Who these studies take

Of the 56 Bacterial Infections studies recruiting now, 38 (68%) set no upper age limit and 13 (23%) stop at 75 or younger; 18 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Bacterial Infections by Shionogi as a file.
02

Study summary

This Phase 1 study will assess the safety, tolerability, and pharmacokinetics (PK) of QPX7831, a beta-lactamase inhibitor, when administered orally in single ascending doses and in multiple ascending doses to heathy adult subjects.

Read the detailed description

Qpex Biopharma, Inc. is developing an oral dosage form that delivers QPX7728, a new boron-based beta-lactamase inhibitor with activity against both serine and metallo-beta-lactamases, for oral treatment in combination with a beta-lactam antibiotic.

The objectives are:

  1. To assess the safety and tolerability of QPX7831 when administered orally in single ascending doses (SAD) and in multiple ascending doses (MAD) to healthy adult subjects.
  2. To assess the PK of single and multiple doses of oral QPX7831 when administered to healthy adult subjects to determine if the target exposures identified in preclinical studies can be attained in healthy adult subjects.
03

Conditions studied

  • Bacterial Infections

Browse trials for

Keywords

  • beta-lactamase inhibitor
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult males and/or females of non-, 18 to 55 years of age (inclusive) at the time of screening.
  2. (BMI) ≥ 18.5 and ≤ 29.9 (kg/m2) and weight between 55.0 and 100.0 kg (inclusive).
  3. Medically healthy with clinically insignificant screening results (e.g., laboratory profiles, medical histories, [ECGs], physical examination) as assessed by the PI.
  4. Voluntarily consent to participate in the study.
  5. Male volunteers must agree to use a condom when engaging in any sexual activity from study check-in through 30 days following the last administration of the study drug, and to not donate sperm during this same period of time. If engaging in sexual activity with a female partner of childbearing potential, an additional method of must be used. Approved additional methods of birth control include:

    1. Intra-uterine device (IUD) in place for at least 3 months prior to Day 1 through 30 days following the final dosing of the study drug.
    2. Barrier method (diaphragm) for at least 14 days prior to Day 1 through 30 days following dosing of the study drug.
    3. Stable hormonal contraceptive for at least 3 months prior to Day 1 through 30 days following dosing of the study drug.
    4. Surgical sterilization (vasectomy) at least 6 months prior to Day 1.
  6. Females of non-childbearing potential with serum FSH levels ≥ 40 mIU/mL are either (defined as 12 months spontaneous amenorrhea) or have undergone one of the following sterilization procedures at least 6 months prior to Day 1 (and is documented):

    1. Bilateral tubal ligation;
    2. Hysterectomy;
    3. Hysterectomy with unilateral or bilateral oophorectomy;
    4. Bilateral oophorectomy.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease.
  2. Positive urine drug/alcohol testing at screening or check-in (Day -1).
  3. Positive testing for (HIV), surface antigen (HBsAg), or antibodies (HCV).
  4. History or presence of alcoholism or drug abuse within the 2 years prior to Day 1.
  5. Use of more than 5 packs/week of cigarettes (or equivalent amount of nicotine-containing product) within 6 months prior to Day 1. Subjects must agree to refrain from smoking for the duration of the study.
  6. Excessive intake of alcohol, defined as an average daily intake of greater than 2 standard drinks for women and 4 standard drinks for men; 1 bottle of beer (375mL) is equivalent to approximately 1.4 standard drinks, 1 glass of spirits (30mL) is equivalent to approximately 1 standard drink and 1 glass (150mL) of wine is equivalent to approximately 1.5 standard drinks.
  7. Use of any prescription medication (with the exception of hormone replacement therapy for females) within 14 days prior to Day 1.
  8. Use of any over the counter (OTC) medication, including herbal products, probiotics and vitamins, within the 7 days prior to Day 1. Up to 2 grams per day of paracetamol is allowed for acute events at the discretion of the PI.
  9. Use of antacids, H2 receptor blockers or proton pump inhibitors within 7 days prior to Day 1.
  10. Documented reaction or anaphylaxis to any medication
  11. Blood donation or significant blood loss (i.e., > 500 mL) within 56 days prior to Day
  12. Plasma donation within 7 days prior to Day 1.
  13. Participation in another clinical trial within 30 days prior to Day 1 or within 5 half-lives of the previous investigational drug, whichever is longer.
  14. Females who are pregnant or lactating.
  15. Surgery within the past three months prior to Day 1 determined by the PI to be .
  16. Any acute illness within 30 days prior to Day 1.
  17. interval >450 msec for males and >470 for females or history of prolonged QT syndrome at screening or check-in (Day -1).
  18. Calculated less than 80 mL/min (Cockcroft-Gault method) at screening or check-in (Day -1).
  19. Subjects who have any clinically significant abnormalities on laboratory values at screening or check-in (Day -1), in particular:

    1. White blood cell count \< 3,000/mm3, \< 11g/dL.
    2. \< 1,200/mm3 or count \< 120,000/mm3.
    3. Liver function abnormalities at screening or check-in (Day -1) (defined by an elevation in , or ALT 1.5 x of the normal range for subjects based on age and sex).
  20. Any other condition or prior therapy, which, in the opinion of the PI, would make the subject unsuitable for this study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    QPX7831 SAD Cohorts

    oral, single ascending dose (or placebo)

    Drug: QPX7831 · Drug: placebo comparator

  • Experimental
    QPX7831 MAD Cohorts

    oral, multiple ascending dose (or placebo)

    Drug: QPX7831 · Drug: placebo comparator

Interventions

  • capsule

  • Drugplacebo comparator

    oral matched placebo capsule

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment -Emergent Adverse events by subject and by cohort (single dose, multiple doses)

    Number of patients with Treatment-Emergent AEs by subject, by cohort, severity and relationship to treatment

    Time frame: up to 17 days

  2. Number of patients with changes from baseline in safety parameters

    Number of patients with changes in safety parameters before and after dosing by subject and cohort

    Time frame: up to 17 days

  3. Peak plasma Concentration measurements by subject and by cohort (Cmax)

    Comparison will be performed between the cohorts for Cmax. Mean graphical presentation of the data will be reported. Statistical analysis of exposure parameters will be performed.

    Time frame: up to 17 days

  4. Time concentration data measurements by subject and by cohort (Tmax)

    Comparison will be performed between the cohorts for Tmax.

    Time frame: up to 17 days

  5. Area under the plasma concentration versus time curve (AUC) between cohorts

    Comparison will be performed between the cohorts for AUC. Mean graphical presentation of the data will be reported. Statistical analysis of exposure parameters will be performed.

    Time frame: up to 17 days

  6. Urine PK amount excreted by subject and by cohort

    Urine PK parameters such as amount excreted will be calculated from urinary excretion data

    Time frame: up to 17 days

  7. Urine PK % dose excreted by subject and by cohort

    Urine PK parameters such as amount of % dose excreted will be calculated from urinary excretion data

    Time frame: up to 17 days

07

Study locations

2 sites
  • Altasciences
    Cypress, California 90630, United States
  • CMAX
    Adelaide, South Australia, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Aug 2022, 16 months.

Of 52 industry-sponsored phase 1 interventional studies under Bacterial Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 16 months is above that.

Counting every sponsor, half of 67 studies reached it within 9 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2020
First posted
Oct 8, 2020
StartActual
Apr 13, 2021
Primary completionActual
Aug 30, 2022
CompletionActual
Aug 30, 2022
Last update
Oct 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04578873
Collaborators
Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
Oct 8, 2020
Start date
Apr 13, 2021
Primary completion
Aug 30, 2022
Completion
Aug 30, 2022
Last update
Oct 10, 2022

Study contacts

Jeffery Loutit, MBChB
study director · Qpex Biopharma, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QPX7831

Start the discussion